RxDoctor Payments Data

William Tennant, MD

Psychiatry · Cullman, ALNPI 1871026609

Payments from drug & device makers

$1,462in general payments, 2019–2025

Across 82 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$516
  • Corium, LLC$250
  • Otsuka America Pharmaceutical, Inc.$144
  • Axsome Therapeutics, Inc.$144
  • Sunovion Pharmaceuticals Inc.$113
  • AbbVie$94
  • plus $202 from 7 others

What the payments were for

  • Food & beverage$1,462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,462 in reported general payments places this provider in the 60th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$11,330
Medicare patients
40
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole11$24,954
FanaptIloperidone11$20,067
AuvelityDextromethorphan Hbr/Bupropion12$12,925
Aripiprazole56$8,284
TrintellixVortioxetine Hydrobromide12$5,252
Bupropion XlBupropion Hcl68$3,375
Duloxetine Hcl94$2,742
Fluoxetine Hcl79$2,099
Lurasidone Hcl29$1,789
Mirtazapine55$1,342
Trazodone Hcl96$1,119
Clozapine22$1,046
Guanfacine Hcl ErGuanfacine Hcl15$951
Divalproex Sodium ErDivalproex Sodium19$942
Quetiapine Fumarate52$921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$144$24,95411 claims
Vanda Pharmaceuticals Inc.Fanapt$16$20,06711 claims
Axsome Therapeutics, Inc.Auvelity$144$12,92512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →